NICE has recommended the use of Lenvima® for untreated, advanced, unresectable hepatocellular carcinoma in adults.
Browsing: Disease Area > Endocrine
Thyroid patients receiving low radiation doses presented similar recurrence rates compared to patients receiving high doses, the HiLo trial has demonstrated.
A marker, termed KIM-1, in the blood could be utilized to predict the risk of developing renal cell carcinoma.
Find out more about Ti-Rads, guidelines for an ultrasound-based risk stratification system to identify nodules that merit biopsy or sonographic follow-up.
The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.
A novel drug shows promise for preventing hearing loss in children after chemotherapy treatment for liver cancer.
A Phase III trial presented at ASCO has suggested that surgery might not be a necessity for patients suffering from advanced kidney cancer.
The FDA has approved the first immuno-oncology combination therapy for patients with advanced renal cell carcinoma.
In a landmark genetics study, a multi-institutional group of researchers have uncovered three distinct evolutionary paths for kidney cancer, allowing them to determine whether a tumor will be aggressive.
Eli Lilly have announced that Cyramza® has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.